Clinical Data unit gets EU patent for cancer-related biomarker

By Mass High Tech Staff

Clinical Data does $50M debt deal [February 26, 2009]

Clinical Data inks partnership in China [January 20, 2009]

Clinical Data to buy Avalon Pharmaceuticals in complex $10M deal [October 28, 2008]

Clinical Data collects $25M from private placement [September 29, 2008]

Clinical Data Inc., a Newton developer of targeted therapeutics and genetic tests, reports that the European Patent Office has granted the firm’s German subsidiary a patent for a genetic biomarker linked to a gene responsible for blocking the absorption of anti-cancer drugs in tumor cells.

The biomarker covered in the patent is used in a genetic test that identifies a common variant of the gene, which is called MDRI. The patent was awarded to Epidauros Biotechnologie AG, the Bernried, Germany, subsidiary of Clinical Data (Nasdaq: CLDA). Clinical Data acquired Epidauros in August 2007 for $11.8 million in cash.

Company officials said the MDRI biomarker is part of a genetic test for drug metabolism that is marketed by Santa Clara, Calif.-based Affymetrix Inc. The Cogenics division of Clinical Data helped Affymetrix develop part of the technology used in the test.

Clinical Data, which employs 459 workers, reported a 2008 net loss of $35.3 million on revenue of $34 million during its fiscal year ending March 31.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.